Wednesday, August 31st, 2016

Summary

 ‘Diabetic Neuropathic Pain - Pipeline Review, H2 2016’, provides an overview of the Diabetic Neuropathic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Neuropathic Pain and features dormant and discontinued projects.

Complete report details @ https://www.wiseguyreports.com/reports/619302-diabetic-neuropathic-pain-pipeline-review-h2-2016        

 

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ https://www.wiseguyreports.com/sample-request/619302-diabetic-neuropathic-pain-pipeline-review-h2-2016   

 

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathic Pain 
- The report reviews pipeline therapeutics for Diabetic Neuropathic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Diabetic Neuropathic Pain therapeutics and enlists all their major and minor projects 
- The report assesses Diabetic Neuropathic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Diabetic Neuropathic Pain

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathic Pain 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Diabetic Neuropathic Pain pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/619302-diabetic-neuropathic-pain-pipeline-review-h2-2016             

 

Key points in table of content

List of Tables 6 
List of Figures 7 
Introduction 8 
Global Markets Direct Report Coverage 8 
Diabetic Neuropathic Pain Overview 9 
Therapeutics Development 10 
Pipeline Products for Diabetic Neuropathic Pain - Overview 10 
Pipeline Products for Diabetic Neuropathic Pain - Comparative Analysis 11 
Diabetic Neuropathic Pain - Therapeutics under Development by Companies 12 
Diabetic Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes 14 
Diabetic Neuropathic Pain - Pipeline Products Glance 15 
Late Stage Products 15 
Clinical Stage Products 16 
Early Stage Products 17 
Diabetic Neuropathic Pain - Products under Development by Companies 18 
Diabetic Neuropathic Pain - Products under Investigation by Universities/Institutes 19 
Diabetic Neuropathic Pain - Companies Involved in Therapeutics Development 20 
APT Therapeutics, Inc. 20 
Astellas Pharma Inc. 21 
BioDelivery Sciences International, Inc. 22 
Bristol-Myers Squibb Company 23 
Centrexion Therapeutics Corp 24 
Chromocell Corporation 25 
Daiichi Sankyo Company, Limited 26 
Grunenthal GmbH 27 
Hydra Biosciences, Inc. 28 
Immune Pharmaceuticals Inc. 29 
Laboratorios Del Dr. Esteve S.A. 30 
Lohocla Research Corporation 31 
Novaremed 32 
PeriphaGen, Inc. 33 
Pharmaleads SA 34 
Prismic Pharmaceuticals, Inc. 35 
Relmada Therapeutics, Inc. 36 
Sphaera Pharma Pvt. Ltd. 37 
Theravasc, Inc. 38 
Diabetic Neuropathic Pain - Therapeutics Assessment 39 
Assessment by Monotherapy Products 39 
Assessment by Combination Products 40 
Assessment by Target 41 
Assessment by Mechanism of Action 43 
Assessment by Route of Administration 45 
Assessment by Molecule Type 47 
Drug Profiles 49 
(amitriptyline + ketamine hydrochloride) - Drug Profile 49 
Product Description 49 
Mechanism Of Action 49 
R&D Progress 49 
(diclofenac sodium + triclocarban) - Drug Profile 52 
Product Description 52 
Mechanism Of Action 52 
R&D Progress 52 
APT-102 - Drug Profile 53 
Product Description 53 
Mechanism Of Action 53 
R&D Progress 53 
AS-1069562 - Drug Profile 55 
Product Description 55 
Mechanism Of Action 55 
R&D Progress 55 
CC-8464 - Drug Profile 56 
Product Description 56 
Mechanism Of Action 56 
R&D Progress 56 
cebranopadol - Drug Profile 57 
Product Description 57 
Mechanism Of Action 57 
R&D Progress 57 
clonidine hydrochloride - Drug Profile 60 
Product Description 60 
Mechanism Of Action 60 
R&D Progress 60 
CNTX-6016 - Drug Profile 63 
Product Description 63 
Mechanism Of Action 63 
R&D Progress 63 
EC-5026 - Drug Profile 64 
Product Description 64 
Mechanism Of Action 64 
R&D Progress 64 
filgrastim - Drug Profile 65 
Product Description 65 
Mechanism Of Action 65 
R&D Progress 65 
GERP-001 - Drug Profile 66 
Product Description 66 
Mechanism Of Action 66 
R&D Progress 66 
HX-100 - Drug Profile 67 
Product Description 67 
Mechanism Of Action 67 
R&D Progress 67 
Kindolor - Drug Profile 69 
Product Description 69 
Mechanism Of Action 69 
R&D Progress 69 
mepivacaine hydrochloride - Drug Profile 70 
Product Description 70 
Mechanism Of Action 70 
R&D Progress 70 
mirogabalin besylate - Drug Profile 71 
Product Description 71 
Mechanism Of Action 71 
R&D Progress 71 
MR-309 - Drug Profile 73 
Product Description 73 
Mechanism Of Action 73 
R&D Progress 73 
NRD-135SE1 - Drug Profile 75 
Product Description 75 
Mechanism Of Action 75 
R&D Progress 75 
palmidrol - Drug Profile 76 
Product Description 76 
Mechanism Of Action 76 
R&D Progress 76 
PGN-305 - Drug Profile 77 
Product Description 77 
Mechanism Of Action 77 
R&D Progress 77 
PL-37 - Drug Profile 78 
Product Description 78 
Mechanism Of Action 78 
R&D Progress 78 
Small Molecule to Activate Kv7.2 for Neuropathic Pain - Drug Profile 79 
Product Description 79 
Mechanism Of Action 79 
R&D Progress 79 
sodium nitrite SR - Drug Profile 80 
Product Description 80 
Mechanism Of Action 80 
R&D Progress 80 
Diabetic Neuropathic Pain - Dormant Projects 82 
Diabetic Neuropathic Pain - Discontinued Products 85 
Diabetic Neuropathic Pain - Product Development Milestones 87 
Featured News & Press Releases 87 
Mar 04, 2016: BioDelivery Sciences to provide an update on Clonidine Topical Gel at the Cowen And Company 36th Annual Healthcare Conference and the 28th Annual Roth Conference 87 
Jan 06, 2016: Hydra Biosciences to Present at the 8th Annual Biotech Showcase Conference in San Francisco on Jan. 11 87 
Sep 28, 2015: Pharmaleads Announces the Opening of French Sites in Its International Phase IIa Clinical Study of PL37 87 
Apr 22, 2015: Pharmaleads Announces the Inclusion of the First Patient in Phase IIa Study of Oral PL37 for Pain in Diabetic Neuropathy 88 
Mar 30, 2015: BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 89 
Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin 90 
Dec 08, 2014: BioDelivery Sciences Announces Completion of Randomization in Phase 3 Trial of Clonidine Topical Gel for the Treatment of Painful Diabetic Neuropathy 91 
Aug 06, 2014: BioDelivery Sciences Provides Update on Ongoing Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy 91 
Oct 30, 2012: Drug Offers New Pain Management Therapy For Diabetics, Study Finds 91 
Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program 92 
Appendix 94 
Methodology 94 
Coverage 94 
Secondary Research 94 
Primary Research 94 
Expert Panel Validation 94 
Contact Us 94 
Disclaimer 95

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=619302

 

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

[email protected]

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)          

 

 

Contact Profile

WiseGuyReports


Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.

Our Market Research Reports and Consulting Services 

Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories. The Wise Guy Reports team prides itself in being the chosen source for market research reports, report customizations services, and other ancillary services such as a Newsletter service and corporate service for large organizations.

Hundreds of large and small organizations across virtually every industry sector worldwide are currently reaping rich dividends from the sharp insights provided by market research reports sourced through Wise Guy Reports. 

Gaining an insight into emerging trends, opportunities and potential threats is key to long-term sustenance in a competitive environment. The handpicked collection of market research reports on Wise Guy Reports is centred on this proven principle.


Norah Trent
P: +44 208 133 9349
M: +1 646 845 9349
W: www.wiseguyreports.com/

Keywords

Diabetic Neuropathic Pain market trend, Diabetic Neuropathic Pain market segmentation, Diabetic Neuropathic Pain market analysis, Diabetic Neuropathic Pain market parameters, Diabetic Neuropathic Pain industry forecast, Diabetic Neuropathic Pain market si

Categories

Newsrooms

Sharing

More Formats

View QR Code